| 000 | 01226 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514193750.0 | ||
| 264 | 0 | _c20040923 | |
| 008 | 200409s 0 0 eng d | ||
| 022 | _a1468-201X | ||
| 024 | 7 |
_a10.1136/hrt.2004.036236 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTownsend, M | |
| 245 | 0 | 0 |
_aConstrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. _h[electronic resource] |
| 260 |
_bHeart (British Cardiac Society) _cAug 2004 |
||
| 300 |
_ae47 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aCabergoline |
| 650 | 0 | 4 |
_aErgolines _xadverse effects |
| 650 | 0 | 4 |
_aFibrosis _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPericarditis, Constrictive _xchemically induced |
| 650 | 0 | 4 |
_aPleura _xpathology |
| 650 | 0 | 4 |
_aPulmonary Fibrosis _xchemically induced |
| 700 | 1 | _aMacIver, D H | |
| 773 | 0 |
_tHeart (British Cardiac Society) _gvol. 90 _gno. 8 _gp. e47 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/hrt.2004.036236 _zAvailable from publisher's website |
| 999 |
_c14956772 _d14956772 |
||